The purpose of this study is to find out if BP2202 is safe and can treat participants with Relapsed/Refractory Multiple Myeloma.
Diagnosis of Multiple Myeloma with relapsed or refractory disease.
Eastern Cooperative Oncology Group (ECOG) Performance Status score of 0 or 1
Adequate organ function.
Have measurable disease
Known active central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of Multiple Myeloma.
Known second malignancy that is progressing or requires active treatment or may interfere with study endpoints.
Single group
BP2202
Biological/VaccineIntravenous infusion
Incidence of dose-limiting toxicities (DLTs; Part A)
Number of participants who experienced a DLT. DLTs include specifically defined adverse events (AEs) considered to be related to BP2202
Incidence of adverse events (AEs; Parts A and B)
Number of participants who experienced AEs, adverse events of special interest (AESIs), or serious adverse events (SAEs)
Overall Response Rate (Parts A and B)
The proportion of participants whose best overall response is Partial Response (PR) or better (PR, VGPR, CR, or sCR) according to IMWG criteria.
Duration of Response (DoR) (Parts A and B)
The time from the first objective response (sCR, CR, VGPR or PR) to the first documented PD according to IMWG criteria or death.
Disease Control Rate (DCR) (Parts A and B)
Number of participants who achieved a best response of sCR, CR, VGPR, PR or SD according to IMWG criteria.
Click on the lead sponsor to view all of their trials.
This trial is not recruiting at the moment. You can still explore other options:
